Journal of Clinical Oncology
Articles in this Issue
The Pancreas Tissue Bank (PCRFTB): Global facilitation of pancreatic research.
e16416 Background: Pancreatic cancer claims > 300,000 lives per year globally. Research into human disease is hampered by lack of availability of well-...
The association between profitability, clinical benefit, and physicians’ selection of cancer drugs.
11074 Background: Compensation for provider-administered cancer drugs (such as intravenous chemotherapy and immunotherapy) is volume-based and proportiona...
RETRACTED: Phase 1 clinical trial of EpCAM CAR-T cell therapy in patients with gastrointestinal cancers.
Recent advances in feature selection methods for breast cancer recurrence prediction: A systematic review.
e13664 Background: Breast cancer recurrence prediction using genomic data faces challenges due to high dimensionality and complex biological relationships...
Shifts in Medicare spending for patients with cancer undergoing chemotherapy following implementation of the Maryland Global Budget Revenue program.
11079 Background: In January 2014, the statewide Maryland Global Budget Revenue (GBR) model was implemented to control the growth in total hospital spendi...
Non- <i>BRCA</i> mutations in breast cancer: Shedding light on radiation outcomes.
e12582 Background: Multigene panel testing has advanced germline mutation detection in breast cancer, extending beyond BRCA 1/2. H...
A panel of four protein tumor markers for effective and affordable lung cancer early detection by artificial intelligence.
8028 Background: Lung cancer is the most common and deadly malignancy worldwide. While low-dose computed tomography (LDCT) reduces mortality in high-risk...
Early on-treatment ctDNA dynamics and response by imaging in patients with sarcoma.
11537 Background: ctDNA holds promise as a prognostic and predictive biomarker for risk stratification and treatment response monitoring across multiple t...
Elevated hernia risk in renal cell carcinoma (RCC) patients treated with tyrosine kinase inhibitors (TKIs): A FAERS analysis.
e16542 Background: TKIs are the cornerstone of targeted therapy for RCC. However, TKIs may increase the risk of hernia development or complications due to...
Phase II propensity-matched controlled trial evaluating metformin as an adjunct to neo-adjuvant, concomitant, and adjuvant temozolomide and hypofractionated-accelerated radiotherapy (M-HART) in glioblastoma patients (NCT02780024).
2064 Background: Phase II, propensity-matched trial, to assess feasibility and toxicity of adding Metformin (MTF) to neo-a...
Predictive values of sarcopenia for unresectable hepatocellular carcinoma treated with transarterial chemoembolization combining atezolizumab plus bevacizumab.
e16281 Background: The relationship between sarcopenia and the prognosis of patients with unresectable hepatocellular carcinoma (uHCC) who underwent trans...
Dynamic combined monitoring of SII and PNI in evaluating the prognostic impact on advanced driver gene–negative NSCLC patients receiving immunotherapy.
e20614 Background: In recent years, immune checkpoint inhibitors (ICIs) have become an important treatment option for patients with advanced, driver gene-...
Assessing efficacy of intrathecal chemotherapy in patients with leptomeningeal metastases: A systematic review and meta-analysis.
e14000 Background: Leptomeningeal metastasis (LM) is a rare and severe complication of cancer, characterized by the spread of malignant cells to the menin...
Racial and ethnic disparities in neuroblastoma incidence and mortality: A systematic review and meta-analysis.
e22008 Background: Neuroblastoma is the solid extracranial tumor most common in the infancy, with a high mortality. Studies shows racial/ethnic disparitie...
Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).
8015 Background: Stage III Non-Small Cell Lung Cancer (NSCLC) is a heterogeneous group of tumors with a wide spectrum of c...
Clinical characteristics, cytogenetic associations, and outcomes in multiple myeloma with chromosome 1q abnormalities.
7541 Background: Multiple myeloma (MM) is characterized by recurrent cytogenetic abnormalities, including translocations involving the immunoglobulin heav...
A phase 1b study investigating the safety, tolerability and preliminary efficacy of HX009 in post-immune checkpoint inhibitor (CPI) therapy advanced melanoma patients.
e14502 Background: Patients with advanced melanoma have limited treatment options post-immune checkpoint inhibitor (CPI) therapy. HX009 is a first-in-clas...
Long-term outcomes in triple-negative breast cancers (TNBC) treated with talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT).
598 Background: TVEC is an engineered herpes simplex oncolytic virus (HSV OV) approved for the treatment of melanoma. We published a phase 1/2 trial combi...
Characterizing platinum resistance in recurrent endometrial cancer: A retrospective cohort study.
e17620 Background: Endometrial cancer is the most diagnosed gynecologic malignancy in Western countries, with a lifetime risk of approximately 2.5% in the...
Diagnostic value of septin-9 methylation assay in the diagnosis of early-stage colorectal cancer and high-grade intraepithelial neoplasia: A systematic review and meta-analysis.
e15666 Background: Colorectal Cancer (CRC) is a major global health burden, accounting for an estimated 10% of all tumour cases and reigning as the third...
Overcoming acquired venetoclax resistance in acute myeloid leukemia through cell metabolism targeting.
6537 Background: Venetoclax is a selective inhibitor of the anti-apoptotic protein BCL2, often overexpressed in acute myeloid leukemia (AML), contributing...
Preliminary results from phase 2 study of prolonged neoadjuvant immunotherapy plus chemotherapy in Borrmann type 4 and large type 3 gastric cancer (Neo-ICEBOAT Study).
e16108 Background: Treatment options for Borrmann Type 4 gastric cancer (Linitis Plastica) have long been a topic of debate. This patient group is charact...
The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes.
7559 Background: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with limited interventions to reduce progression to...
DEFENDOR SPECIAL: Effect of primary prophylaxis with empegfilgrastim on pCR rate after neoadjuvant TCHP in early HER2+ breast cancer patients—Matching-adjusted indirect comparison (MAIC).
e13011 Background: TCHP (docetaxel, carboplatin, trastuzumab plus pertuzumab) is a preferred regimen for neoadjuvant therapy (NAT) of HER2-positive early...
Microbial metabolic pathways to abrogate immunotherapy toxicity and promote anti-tumor response in metastatic renal cell cancer.
3063 Background: Metastatic RCC has a poor prognosis. Despite improvement in treatment outcomes with ICB and targeted therapy, many patients fail to respo...